



ORAL PRESENTATION

Open Access

# The combination of arsenic, interferon-alpha, and zidovudine restores an “immunocompetent-like” micro-environment in patients with adult T-cell leukemia lymphoma

Ghada Kchour<sup>1</sup>, SA Rahim Rezaee<sup>2</sup>, Reza Farid<sup>3</sup>, Akram Ghantous<sup>4</sup>, Houshang Rafatpana<sup>3</sup>, Mahdi Tahrini<sup>5</sup>, Mohamad-Mehdi Kooshyar<sup>6</sup>, Hiba El Hajj<sup>7</sup>, Fadwa Berry<sup>1</sup>, Roudaina Nasser<sup>7</sup>, Abbas Shirdel<sup>6</sup>, Zeina Dassouki<sup>7</sup>, Mohamad Ezzedine<sup>1</sup>, Hossein Rahimi<sup>6</sup>, Ardeshir Ghavamzadeh<sup>8</sup>, Hugues de Thé<sup>9</sup>, Olivier Hermine<sup>10</sup>, Mahmoud Mahmoudi<sup>3</sup>, Ali Bazarbachi<sup>7\*</sup>

From 16th International Conference on Human Retroviruses: HTLV and Related Viruses  
Montreal, Canada. 26-30 June 2013

HTLV-I associated adult T-cell leukemia/lymphoma (ATL) carries a dismal prognosis due to chemo-resistance and immuno-compromised micro-environment. The combination of zidovudine and interferon-alpha (IFN) significantly improved survival in ATL. Promising results were reported by adding arsenic trioxide to zidovudine and IFN. Here we assessed Th1/Th2/T<sub>reg</sub> cytokine gene expression profiles in 16 ATL patients before and 30 days after treatment with arsenic/IFN/zidovudine, in comparison with HTLV-I healthy carriers and sero-negative blood donors. ATL patients at diagnosis displayed a T<sub>reg</sub>/Th2 cytokine profile with significantly elevated transcript levels of Foxp3, interleukin-10 (IL-10), and IL-4 and had a reduced Th1 profile evidenced by decreased transcript levels of interferon- $\gamma$  (IFN- $\gamma$ ) and IL-2. Most patients (15/16) responded, with CD4<sup>+</sup>CD25<sup>+</sup> cells significantly decreasing after therapy, paralleled by decreases in Foxp3 transcript. Importantly, arsenic/IFN/zidovudine therapy sharply diminished IL-10 transcript and serum levels concomitant with decrease in IL-4 and increases in IFN- $\gamma$  and IL-2 mRNA, whether or not values were adjusted to the percentage of CD4<sup>+</sup>CD25<sup>+</sup> cells. The observed shift from a T<sub>reg</sub>/Th2 phenotype before treatment toward a Th1 phenotype after treatment with arsenic/IFN/zidovudine may play an important role in restoring an immuno-competent

micro-environment, which enhances the eradication of ATL cells and the prevention of opportunistic infections.

#### Authors' details

<sup>1</sup>Department of Biology, Faculty of Sciences, Lebanese University, Hadath, Lebanon. <sup>2</sup>Microbiology and Virology Research Center, Bu-Ali Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran. <sup>3</sup>Immunology Research Centre Bu-Ali Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran. <sup>4</sup>Lebanese American University, School of Arts and Sciences, Lebanon. <sup>5</sup>Islamic University, Faculty of Nursing Sciences, Lebanon. <sup>6</sup>Department of Internal Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. <sup>7</sup>Department of Internal Medicine, American University of Beirut, Beirut, Lebanon. <sup>8</sup>Tehran University of Medical Sciences, Tehran, Iran. <sup>9</sup>INSERM UMR 944 and CNRS UMR 7212, Hôpital Saint Louis, Paris, France. <sup>10</sup>CNRS UMR 8147, Hôpital Necker, Paris, France.

Published: 7 January 2014

doi:10.1186/1742-4690-11-S1-O4

**Cite this article as:** Kchour *et al.*: The combination of arsenic, interferon-alpha, and zidovudine restores an “immunocompetent-like” micro-environment in patients with adult T-cell leukemia lymphoma.

*Retrovirology* 2014 **11**(Suppl 1):O4.

<sup>7</sup>Department of Internal Medicine, American University of Beirut, Beirut, Lebanon

Full list of author information is available at the end of the article